LeadershipAPLT has announced John H. Johnson, an industry veteran with more than 40 years of experience, will serve as Executive Chairman, and Les Funtleyder, who is currently the CFO and has served on APLT's board, will serve as interim CEO.
Market PotentialThere was an expected share price return of over 310%, indicating significant potential upside.
Regulatory ProgressThe NDA for SORD will be reviewed by the Neurology 1 division at the FDA, with whom the company aligned on plans for an accelerated approval application.